keyword
MENU ▼
Read by QxMD icon Read
search

Colistimethate

keyword
https://www.readbyqxmd.com/read/28172481/low-doses-of-colistimethate-don-t-rush-in
#1
Alexandre P Zavascki, Roger L Nation
No abstract text is available yet for this article.
December 13, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28065254/pulmonary-eosinophilia-from-inhaled-colistin
#2
Pierre-Alexis Lépine, Alain Dumas, Louis-Philippe Boulet
We report the case of a patient with a history of chronic bronchiectasis that presented with new onset fatigue, shortness of breath, peripheral blood eosinophilia and infiltrates on chest radiograph. Eight days previously, she was prescribed inhaled colistimethate sodium 75 mg bid to prevent exacerbations of her respiratory condition. To our knowledge, our case is the first to show the clinical and radiologic features of inhaled-colistimethate-induced pulmonary eosinophilia. It also shows the rapid resolution of its features following treatment with oral corticosteroids...
January 2017: Chest
https://www.readbyqxmd.com/read/28056821/impact-of-colistin-plasma-levels-on-the-clinical-outcome-of-patients-with-infections-caused-by-extremely-drug-resistant-pseudomonas-aeruginosa
#3
Luisa Sorlí, Sonia Luque, Concepción Segura, Nuria Campillo, Milagro Montero, Erika Esteve, Sabina Herrera, Natividad Benito, Francisco Alvarez-Lerma, Santiago Grau, Juan Pablo Horcajada
BACKGROUND: Colistin has a narrow therapeutic window with nephrotoxicity being the major dose-limiting adverse effect. Currently, the optimal doses and therapeutic plasma levels are unknown. METHODS: Prospective observational cohort study, including patients infected by colistin-susceptible P. aeruginosa treated with intravenous colistimethate sodium (CMS). Clinical data and colistin plasma levels at steady-state (Css) were recorded. The primary and secondary end points were clinical cure and 30-day all-cause mortality...
January 5, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28011614/dosing-guidance-for-intravenous-colistin-in-critically-ill-patients
#4
Roger L Nation, Samira M Garonzik, Visanu Thamlikitkul, Evangelos J Giamarellos-Bourboulis, Alan Forrest, David L Paterson, Jian Li, Fernanda P Silveira
BACKGROUND: Intravenous colistin is difficult to use because plasma concentrations for antibacterial effect overlap those causing nephrotoxicity, and there is large inter-patient variability in pharmacokinetics. The aim was to develop dosing algorithms for achievement of a clinically desirable average steady-state plasma colistin concentration (Css,avg) of 2mg/L. METHODS: Plasma concentration-time data from 214 adult critically-ill patients (creatinine clearance 0-236mL/min; 29 receiving renal replacement therapy (RRT)) were subjected to population pharmacokinetic analysis...
December 23, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28007722/physical-compatibility-of-isavuconazonium-sulfate-with-select-i-v-drugs-during-simulated-y-site-administration
#5
Wonhee So, Liz Kim, Abrar K Thabit, David P Nicolau, Joseph L Kuti
PURPOSE: The physical compatibility of isavuconazonium sulfate with 95 i.v. drugs during simulated Y-site administration was studied. METHODS: Isavuconazonium sulfate for injection and all other drugs were reconstituted according to the manufacturer's recommendation and further diluted with 0.9% sodium chloride injection or 5% dextrose injection to a final concentration (1.5 mg/mL for isavuconazonium sulfate and standard concentrations used clinically for other drugs)...
January 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28007716/optimizing-colistin-dosing-is-a-loading-dose-necessary
#6
Lama H Nazer, Nadine Anabtawi
PURPOSE: Published literature on the pharmacokinetics and effectiveness of colistin loading doses is reviewed. SUMMARY: Colistin is increasingly used to treat infections caused by multidrug-resistant (MDR) gram-negative bacteria (GNB). A literature search identified seven reports on studies of colistin loading doses. All reviewed studies involved small samples of critically ill patients, with considerable variation in the colistin products and loading doses used...
January 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27993859/nephrotoxicity-of-polymyxins-is-there-any-difference-between-colistimethate-and-polymyxin-b
#7
REVIEW
Alexandre P Zavascki, Roger L Nation
Nephrotoxicity is a common adverse effect of the clinically used polymyxins, colistin and polymyxin B. This adverse effect is dose limiting for both polymyxins, as the plasma polymyxin concentrations associated with renal damage overlap those required for antibacterial effect. Since development of acute kidney injury (AKI) during therapy is highly undesirable, it is extremely important to know whether there is any difference between the nephrotoxic potential of colistin (administered as its inefficient prodrug, colistimethate) and polymyxin B (administered as the active form)...
March 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27986687/low-doses-of-colistimethate-don-t-rush-in
#8
Alexandre P Zavascki, Roger L Nation
No abstract text is available yet for this article.
December 16, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27743779/colistin-loading-dose-evaluation-of-the-published-pharmacokinetic-and-clinical-data
#9
REVIEW
Konstantinos Z Vardakas, Konstantinos Rellos, Nikolaos A Triarides, Matthew E Falagas
Colistin (polymyxin E) has been widely used since the beginning of the century as a last-option antibiotic for the treatment of patients with multidrug-resistant and extensively-drug resistant bacterial infections. However, colistin dosing is troublesome because each batch of the drug contains a mixture of components and because it is administered as the inactive pro-drug colistimethate sodium (CMS), which has different pharmacokinetic (PK) properties from the active drug. Significant inter-individual and intra-individual variability in colistin plasma concentrations have been observed in all available studies...
November 2016: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27692977/comparison-of-inhaled-antibiotics-for-the-treatment-of-chronic-pseudomonas-aeruginosa-lung-infection-in-patients-with-cystic-fibrosis-systematic-literature-review-and-network-meta-analysis
#10
J Stuart Elborn, Anne-Lise Vataire, Ayako Fukushima, Samuel Aballea, Amine Khemiri, Curtis Moore, Goran Medic, Michiel E H Hemels
PURPOSE: In Europe, 4 inhaled antibiotics (tobramycin, colistimethate sodium, aztreonam, and levofloxacin) are currently approved for the treatment of chronic Pseudomonas aeruginosa lung infection in patients with cystic fibrosis (CF). Levofloxacin inhalation solution (LIS) is the most recently approved inhaled antibiotic for adult patients with CF. A systematic literature review and Bayesian network meta-analysis (NMA) was conducted to compare the relative short-term (4 weeks) and long-term (24 weeks) outcomes of these inhaled antibiotics versus LIS...
October 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27684296/determination-of-colistin-and-colistimethate-levels-in-human-plasma-and-urine-by-high-performance-liquid-chromatography-tandem-mass-spectrometry
#11
Kevin Bihan, Qin Lu, Manon Enjalbert, Maxime Apparuit, Olivier Langeron, Jean-Jacques Rouby, Christian Funck-Brentano, Noël Zahr
BACKGROUND: Colistin is a polypeptide antibiotic from the polymyxin E group used for the treatment of infections caused by multidrug-resistant gram-negative bacteria. The main constituents, accounting for approximately 85% of this mixture, are colistin A (polymyxin E1) and colistin B (polymyxin E2). The aim of this study was to develop and validate new and fast methods of quantification of colistin A and B and its precursors [colistin methanesulfonate sodium (CMS) A and B] by ultraperformance liquid chromatography-tandem mass spectrometry in plasma and urine with short pretreatment and run times...
December 2016: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/27682964/stability-study-of-sodium-colistimethate-loaded-lipid-nanoparticles
#12
M Moreno-Sastre, M Pastor, A Esquisabel, E Sans, M Viñas, D Bachiller, J L Pedraz
In the last decades, the encapsulation of antibiotics into nanoparticulate carriers has gained increasing attention for the treatment of infectious diseases. Sodium colistimethate-loaded solid lipid nanoparticles (Colist-SLNs) and nanostructured lipid carriers (Colist-NLCs) were designed aiming to treat the pulmonary infection associated to cystic fibrosis patients. The nanoparticles were freeze-dried using trehalose as cryoprotectant. The stability of both nanoparticles was analysed over one year according to the International Conference of Harmonisation (ICH) guidelines by determining the minimum inhibitory concentration (MIC) against clinically isolated Pseudomonas aeruginosa strains and by studying their physico-chemical characteristics...
November 2016: Journal of Microencapsulation
https://www.readbyqxmd.com/read/27670739/high-throughput-cell-based-assay-for-identification-of-glycolate-oxidase-inhibitors-as-a-potential-treatment-for-primary-hyperoxaluria-type-1
#13
Mengqiao Wang, Miao Xu, Yan Long, Sonia Fargue, Noel Southall, Xin Hu, John C McKew, Christopher J Danpure, Wei Zheng
Glycolate oxidase (GO) and alanine:glyoxylate aminotransferase (AGT) are both involved in the peroxisomal glyoxylate pathway. Deficiency in AGT function causes the accumulation of intracellular oxalate and the primary hyperoxaluria type 1 (PH1). AGT enhancers or GO inhibitors may restore the abnormal peroxisomal glyoxylate pathway in PH1 patients. With stably transformed cells which mimic the glyoxylate metabolic pathway, we developed an indirect glycolate cytotoxicity assay in a 1,536-well plate format for high throughput screening...
September 27, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27570987/evaluation-of-the-in-vitro-ocular-toxicity-of-the-fortified-antibiotic-eye-drops-prepared-at-the-hospital-pharmacy-departments
#14
Anxo Fernández-Ferreiro, Miguel González-Barcia, María Gil-Martínez, María Santiago Varela, María Pardo, José Blanco-Méndez, Antonio Piñeiro-Ces, María Jesús Lamas Díaz, Francisco J Otero-Espinar
The use of parenteral antibiotic eye drop formulations with non-marketed compositions or concentrations, commonly called fortified antibiotic eye drops, is a common practice in Ophthalmology in the hospital setting. The aim of this study was to evaluate the in vitro ocular toxicity of the main fortified antibiotic eye drops prepared in the Hospital Pharmacy Departments. We have conducted an in vitro experimental study in order to test the toxicity of gentamicin, amikacin, cefazolin, ceftazidime, vancomycin, colistimethate sodium and imipenem-cilastatin eye drops; their cytotoxicity and acute tissue irritation have been evaluated...
September 1, 2016: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/27551008/successful-treatment-of-bloodstream-infection-due-to-metallo-%C3%AE-lactamase-producing-stenotrophomonas-maltophilia-in-a-renal-transplant-patient
#15
Maria F Mojica, Christopher P Ouellette, Amy Leber, M Brian Becknell, Monica I Ardura, Federico Perez, Masako Shimamura, Robert A Bonomo, Samuel L Aitken, Samuel A Shelburne
Stenotrophomonas maltophilia is an emerging multidrug-resistant (MDR) opportunistic pathogen for which new antibiotic options are urgently needed. We report our clinical experience treating a 19-year-old renal transplant recipient who developed prolonged bacteremia due to metallo-β-lactamase-producing S. maltophilia refractory to conventional treatment. The infection recurred despite a prolonged course of colistimethate sodium (colistin) but resolved with the use of a novel drug combination with clinical efficacy against the patient's S...
September 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27543655/predicting-the-risk-of-nephrotoxicity-in-patients-receiving-colistimethate-sodium-a-multicentre-retrospective-cohort-study
#16
Kady Phe, Ryan K Shields, Frank P Tverdek, Samuel L Aitken, David J Guervil, Wai-Ying M Lam, Rachel J Musgrove, Andrea M Luce, Vincent H Tam
OBJECTIVES: With increasing rates of infections caused by MDR Gram-negative organisms, clinicians resort to older agents such as colistimethate sodium (CMS) despite a significant risk of nephrotoxicity. Several risk factors for CMS-associated nephrotoxicity have been reported, but they have yet to be validated. We compared the performance of published mathematical models in predicting the risk of CMS-associated nephrotoxicity. METHODS: In a multicentre, retrospective, cohort study, adult patients (≥18 years of age) were evaluated from five large academic medical centres in the USA...
December 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27540243/setting-up-of-a-homecare-system-for-high-cost-nebulisers-in-a-paediatric-cystic-fibrosis-centre
#17
Veronica Chorro-Mari, Nanna Christiansen
AIM: Due to national changes to the commissioning process of high cost nebulisers (HCN) for Cystic Fibrosis (CF) patients, CF centres have to repatriate the prescribing of the HCN to the tertiary care centres.1 The following nebulisers will no longer be prescribed by primary care: Cayston® (Aztreonam); Colomycin®, Pomixin®, Clobreathe® (Colistimethate); Pulmozyme® (Dornase alfa); Tobi®, Tobi Podhaler ®, Bramitob® (Tobramycin).This abstract explains how the Royal London Hospital (RLH) Paediatric Pharmacy recruited over 100 paediatric (CF) patients smoothly within a period of 4 months and set up a homecare system to avoid patients and families having to travel large distances to obtain their medication...
September 2016: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/27393775/chronic-rhinosinusitis-in-patients-with-cystic-fibrosis
#18
Daniel L Hamilos
Chronic rhinosinusitis (CRS) is highly prevalent in patients with cystic fibrosis (CF) and accounts for significant morbidity and contribution to CF lung disease. Mutations of the cystic fibrosis transmembrane regulator gene occur with increased prevalence in patients with CRS without CF, suggesting some contribution to CRS pathophysiology. Nasal polyps (NPs) occur with increased prevalence in patients with CF of all ages and have a more neutrophilic appearance with fewer eosinophils and increased submucosal glandular elements in comparison to NPs from patients without CF...
July 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27291693/ten-years-with-colistin-a-retrospective-case-series
#19
D E Katz, D Marchaim, M V Assous, A Yinnon, Y Wiener-Well, E Ben-Chetrit
OBJECTIVE: At the Shaare Zedek Medical Center, we have been using colistimethate sodium (CMS) for empiric as well as pathogen-directed treatment. We present our 10-year experience. METHODS: We conducted a retrospective case-series analysis of patients admitted from 1 January 2004 through 1 May 2014 who received at least one dose of CMS. Patient characteristics analysed for all admission for which patients received CMS, included: age, number of re-admissions, admission ward, renal function, disposition and microbiology results...
September 2016: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/27276179/pharmacokinetics-of-colistin-following-a-single-dose-of-intravenous-colistimethate-sodium-in-critically-ill-neonates
#20
Narongsak Nakwan, Siripa Usaha, Kulkanya Chokephaibulkit, Paola Villani, Mario Regazzi, Roberto Imberti
In this study, we sought to evaluate the pharmacokinetics of colistin after intravenous administration of colistimethate sodium (CMS) in the critically ill neonates with Gram-negative bacterial infections. A single intravenous dose of CMS [approximately 150,000 IU/kg, equivalent to 5 mg/kg colistin base activity (CBA)] was administered to 7 critically ill neonates. Mean (±SD) maximum plasma colistin concentration and area under the time-concentration curve from 0 to infinity were 3.0 ± 0.7 µg/mL and 25...
November 2016: Pediatric Infectious Disease Journal
keyword
keyword
44346
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"